Novello S - Search Results

1

Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer.

Vavalà T, Mariniello A, Novello S. Vavalà T, et al. Among authors: novello s. Transl Cancer Res. 2019 Jan;8(Suppl 1):S48-S54. doi: 10.21037/tcr.2018.10.23. Transl Cancer Res. 2019. PMID: 35117063 Free PMC article. Review.

2

Lung cancer and women.

Novello S, Vavalà T. Novello S, et al. Future Oncol. 2008 Oct;4(5):705-16. doi: 10.2217/14796694.4.5.705. Future Oncol. 2008. PMID: 18922127 Review.

3

Maintenance therapy in NSCLC: why? To whom? Which agent?

Novello S, Milella M, Tiseo M, Banna G, Cortinovis D, Di Maio M, Garassino M, Maione P, Martelli O, Vavalà T, Bria E. Novello S, et al. J Exp Clin Cancer Res. 2011 May 6;30(1):50. doi: 10.1186/1756-9966-30-50. J Exp Clin Cancer Res. 2011. PMID: 21548925 Free PMC article. Review.

4

Emerging new agents for the management of patients with non-small cell lung cancer.

Capelletto E, Novello S. Capelletto E, et al. Among authors: novello s. Drugs. 2012 Jun 19;72 Suppl 1:37-52. doi: 10.2165/1163028-S0-000000000-00000. Drugs. 2012. PMID: 22712796 Review.

5

Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.

Novello S, Vavalà T, Levra MG, Solitro F, Pelosi E, Veltri A, Scagliotti GV. Novello S, et al. Clin Lung Cancer. 2013 May;14(3):230-7. doi: 10.1016/j.cllc.2012.10.004. Epub 2012 Dec 29. Clin Lung Cancer. 2013. PMID: 23276821 Clinical Trial.

6

ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway.

Lo Iacono M, Monica V, Vavalà T, Gisabella M, Saviozzi S, Bracco E, Novello S, Papotti M, Scagliotti GV. Lo Iacono M, et al. Among authors: novello s. Int J Cancer. 2015 Jun 1;136(11):2598-609. doi: 10.1002/ijc.29302. Epub 2014 Nov 12. Int J Cancer. 2015. PMID: 25359574 Free article.

7

Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome.

Righi L, Vavalà T, Rapa I, Vatrano S, Giorcelli J, Rossi G, Capelletto E, Novello S, Scagliotti GV, Papotti M. Righi L, et al. Among authors: novello s. J Thorac Oncol. 2014 Oct;9(10):1540-6. doi: 10.1097/JTO.0000000000000271. J Thorac Oncol. 2014. PMID: 25521399 Free article.

8

MET inhibition in lung cancer.

Menis J, Giaj Levra M, Novello S. Menis J, et al. Among authors: novello s. Transl Lung Cancer Res. 2013 Feb;2(1):23-39. doi: 10.3978/j.issn.2218-6751.2012.12.04. Transl Lung Cancer Res. 2013. PMID: 25806202 Free PMC article. Review.

9

Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures.

Carnio S, Novello S, Papotti M, Loiacono M, Scagliotti GV. Carnio S, et al. Among authors: novello s. Transl Lung Cancer Res. 2013 Oct;2(5):372-81. doi: 10.3978/j.issn.2218-6751.2013.10.05. Transl Lung Cancer Res. 2013. PMID: 25806256 Free PMC article. Review.

10

Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice.

Novello S, Capelletto E, Cortinovis D, Tiseo M, Galetta D, Valmadre G, Casartelli C, Rapetti SG, Rossi A. Novello S, et al. Transl Lung Cancer Res. 2014 Jun;3(3):173-80. doi: 10.3978/j.issn.2218-6751.2014.06.10. Transl Lung Cancer Res. 2014. PMID: 25806297 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

498 results

Search Page